Skip to main content

Advertisement

Table 2 Summary of costs (NIS at 2010 price levels) and QALY losses of proposed universal GBS screening versus current risk-factor screening

From: Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis

   Incremental
  Current Proposed Change
Screening Costs 617,408 3,498,644 2,881,236
Treatment Savings –614,683 –2,550,420 –1,935,737
lifetime productivity gains –256,990 –1,068,618 –811,628
Net Cost to Society –254,266 –120,394 133,872
Mortality QALYs lost 34.97 23.87 –11.10
Morbidity QALYs lost 0.56 0.24 –0.32
Sequellae QALYs lost 1.97 0.81 –1.16
Total QALYS lost 37.50 24.92 –12.58